Hepatic and intestinal first-pass effects of Oltipraz in rats

被引:17
作者
Bae, SK
Kim, JW
Kim, YH
Kim, YG
Kim, SG
Lee, MG
机构
[1] Seoul Natl Univ, Coll Pharm, Seoul 151742, South Korea
[2] Seoul Natl Univ, Pharmaceut Sci Res Inst, Seoul 151742, South Korea
[3] CJ Corp, Inst Sci & Technol, R&D Ctr Pharmaceut, Inchon, South Korea
[4] Dankook Univ, Coll Med, Dept Pharmacol, Chunan, South Korea
关键词
oltipraz; hepatic and intestinal first-pass effects; rats;
D O I
10.1002/bdd.439
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
It was reported that the mean value of the extent of absolute oral bioavailability (F) of oltipraz at a dose of 20 mg/kg was 41.2% and only 2.68% of the oral dose was unabsorbed from the gastrointestinal tract in rats. Hence, the low F in rats could be due to considerable first-pass (gastric, intestinal and hepatic) effects. Hence, the first-pass effects of oltipraz were measured after intravenous, intraportal, intragastric and intraduodenal administration of the drug at a dose of 20 mg/kg to rats. The total area under the plasma concentration-time curve from time zero to time infinity (AUC) values between intragastric and intraduodenal administration (213 and 212 mu g min/ml) in rats were almost similar, but the values were significantly smaller than that after intraportal administration (316 mu g min/ml) in rats, indicating that gastric first-pass effect was almost negligible (due to negligible absorption of oltipraz from rat stomach), but the intestinal first-pass effect of oltipraz was considerable, approximately 32% of the oral dose. The hepatic first-pass effect of oltipraz was approximately 40% based on AUC values between intravenous and intraportal administration (319 versus 536 mu g min/ml). Since approximately 65% of the oral oltipraz was absorbed into the portal vein, the value of 40% was equivalent to 25% of the oral dose. The low F of oltipraz in rats was mainly due to considerable hepatic and intestinal first-pass effects. Copyright (c) 2005 John Wiley & Sons, Ltd.
引用
收藏
页码:129 / 134
页数:6
相关论文
共 13 条
[1]   Interspecies pharmacokinetic scaling of oltipraz in mice, rats, rabbits and dogs, and prediction of human pharmacokinetics [J].
Bae, SK ;
Lee, SJ ;
Kim, YG ;
Kim, SH ;
Kim, JW ;
Kim, T ;
Lee, MG .
BIOPHARMACEUTICS & DRUG DISPOSITION, 2005, 26 (03) :99-115
[2]  
Bae SK, 2001, RES COMMUN MOL PATH, V110, P133
[3]   NEW CALCULATION METHOD OF MEAN TOTAL-BODY CLEARANCE OF DRUGS AND ITS APPLICATION TO DOSAGE REGIMENS [J].
CHIOU, WL .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1980, 69 (01) :90-91
[4]   DETERMINATION OF OLTIPRAZ IN SERUM BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH OPTICAL ABSORBENCY AND MASS-SPECTROMETRIC DETECTION [J].
CHRISTENSEN, RG ;
MALONE, W .
JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1992, 584 (02) :207-212
[5]   PHYSIOLOGICAL-PARAMETERS IN LABORATORY-ANIMALS AND HUMANS [J].
DAVIES, B ;
MORRIS, T .
PHARMACEUTICAL RESEARCH, 1993, 10 (07) :1093-1095
[6]   PHARMACOKINETICS OF DIAZEPAM FOLLOWING MULTIPLE-DOSE ORAL-ADMINISTRATION TO HEALTHY HUMAN SUBJECTS [J].
EATMAN, FB ;
COLBURN, WA ;
BOXENBAUM, HG ;
POSMANTER, HN ;
WEINFELD, RE ;
RONFELD, R ;
WEISSMAN, L ;
MOORE, JD ;
GIBALDI, M ;
KAPLAN, SA .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1977, 5 (05) :481-494
[7]  
GIBALDI M, 1982, PHRAMACOKINETICS
[8]   Liver and gastrointestinal first-pass effects of azosemide in rats [J].
Kim, J ;
Kim, SH ;
Lee, MG .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1997, 49 (09) :878-883
[9]   PHARMACOKINETICS AND PHARMACODYNAMICS OF FUROSEMIDE IN PROTEIN-CALORIE MALNUTRITION [J].
KIM, SH ;
CHOI, YM ;
LEE, MG .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1993, 21 (01) :1-17
[10]  
LITTERST CL, 1975, DRUG METAB DISPOS, V3, P259